The Bull Rankings scorecard — our quality-growth score is 72 / 100, built from three pillars scored 0–100: Quality 78, Growth 100, Value 57 (valuation is judged against sector peers).
The thesis
The market prices argenx as a growth leader, and the numbers back it up. Revenue grew 89.6% year-over-year, profit margins sit at 32.3%, and return on equity clocks in at 23.6%. Our model gives the company a 72/100 quality-growth score, with growth at a perfect 100 and value at 57, slightly on the cheap side of peers. The growth pillar is the story here, not the valuation. The stock trades at 39.4 times trailing earnings, a premium that only makes sense if the pipeline keeps delivering. The bear will argue the multiple is too rich, and our model cannot read a five‑year return‑on‑capital history for argenx at all — that leg of the quality score is missing rather than passed.
What the business actually is
argenx sells a single franchise built around efgartigimod, the antibody fragment at the heart of VYVGART and VYVGART HYTRULO. These drugs treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and could soon add autoimmune myositis after the positive Phase 3 ALKIVIA trial. The pipeline extends efgartigimod into seronegative gMG, ocular myasthenia gravis, Graves’ disease, Sjögren’s, and systemic sclerosis, while empasiprubart and adimanebart chase rare neuromuscular disorders like multifocal motor neuropathy and congenital myasthenic syndrome. The revenue engine is the gMG franchise, with VYVGART already approved and reimbursed in multiple markets, and the recent myositis win could add another high-value indication.
Why it can (or can't) keep compounding
Return on equity at 23.6% says the business turns capital into profit efficiently, and the 32.3% profit margin shows pricing power in autoimmune care. The moat is the antibody engineering platform that yields differentiated Fc fragments with fewer side effects and longer dosing intervals than rivals. Competitors can’t replicate the platform overnight; even if they reverse-engineer the mechanism, the regulatory path for biologics is years long. Our model cannot compute a five‑year return‑on‑capital history here, though the returns it can see suggest the platform is real. The growth pillar at 100/100 reflects the 89.6% revenue growth, which is explosive for a commercial-stage biotech. If the pipeline keeps converting, the compounding can continue.
The valuation question
The P/E of 39.4 prices in a lot of growth, though not more than the business is delivering. Our model’s weakest pillar—value at 57—puts the stock only slightly on the cheap side of peers. Analysts see it the same way: the 12-month target range stretches from $770 to $1350, with a mean of $1098.32, implying 6% upside from the current price. The recent price-target bumps from Truist, RBC, HC Wainwright, and Citizens all hinge on the autoimmune myositis win and the expanding label set. The market is betting on a durable franchise, not a one-hit wonder.
The bear case
The bear’s strongest argument is the PEG ratio of 1.31, which suggests the growth premium is already rich. With a debt-to-equity of 0.01, the balance sheet isn’t the risk—it’s the sustainability of the 89.6% growth rate. If new indications slow or reimbursement pressure mounts, the multiple could compress fast. That missing history is another caution: the platform’s promise hasn’t been tested through a full cycle of competition and pricing scrutiny.
What would change our mind
First, a slowdown in revenue growth below 50% year-over-year would break the growth pillar that supports the thesis. Second, if the profit margin dips below 30%, the durability of the franchise comes into question. Third, any safety signal in the pipeline—especially in the newer indications—would force a reassessment of the platform’s moat. Until then, the numbers are what they are: a high-quality compounder priced for continued success.